The Health and Human Services Inspector General has again opted not to take a position on a request by drugmakers to exempt value-based contracts from anti-kickback law, InsideHealthPolicy reports.
The IG’s decision to stand clear of a position comes as President Donald Trump’s administration says it is working on strategies to drive down drug costs, including a potential rework of the anti-kickback law’s safe harbor guidelines.
According to InsideHealthPolicy, some analysts believe the government could change those guidelines, but the HHS’ role remains mostly unclear.
Click here to read the full report on InsideHealthPolicy. (Paid subscription required)